French pharmaceutical company Sanofi has recently teamed up with artificial intelligence (AI) firm OpenAI and tech-driven pharmaceutical company Formation Bio to develop AI-powered software aimed at enhancing drug development processes and delivering new medications to patients more effectively.
Together, the companies are set to integrate data, software, and tailored models to create specialized solutions across the drug development cycle. Sanofi’s CEO, Paul Hudson, expressed that the customization of next-generation AI models will play a crucial role in revolutionizing drug development and providing innovative treatments to patients eagerly awaiting them.
Sanofi plans to utilize this collaboration to utilize proprietary data for developing AI models as part of its goal to become the first biopharma company operating at scale with AI technology. OpenAI will bring to the table advanced AI capabilities, model fine-tuning abilities, deep expertise in AI, along with dedicated resources and thought partnership.
Brad Lightcap, COO of OpenAI, highlighted the immense potential of AI in expediting drug development processes and bringing new medicines to the market. Additionally, Formation Bio will contribute extensive engineering resources, expertise in the pharma-AI intersection, and its tech-driven development platform to create and deploy AI technologies throughout the pharmaceutical lifecycle.
Benjamine Liu, Co-Founder & CEO of Formation Bio, emphasized that by implementing customized AI agents and models specific to the industry, companies like Sanofi and Formation Bio can significantly enhance productivity and revolutionize the pace at which new medications are introduced to patients.
This strategic partnership signifies a step toward leveraging technology to innovate drug development processes and potentially transform the pharmaceutical landscape for the benefit of patients and their families.
